SYS-CON MEDIA Authors: Cynthia Dunlop, Mark O'Neill, Kevin Benedict, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

Insys Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference

PHOENIX, AZ -- (Marketwired) -- 01/06/14 -- Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will present at the 32nd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2014 at the Westin St. Francis Hotel in San Francisco.

Michael L. Babich, President and Chief Executive Officer, will host the presentation on Thursday, January 16, 2014 at 1:00 p.m. PST.

During this presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of this presentation during the event, please visit: www.insysrx.com. A replay of this webcast will be available for 30 days after the initial presentation.

About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.

Contact:
Lisa M. Wilson
President
In-Site Communications, Inc.
212-452-2793

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.